Impact of changes to cervical screening guidelines on age and interval at which women are tested: Population-based study.


Journal

Journal of medical screening
ISSN: 1475-5793
Titre abrégé: J Med Screen
Pays: England
ID NLM: 9433359

Informations de publication

Date de publication:
09 2021
Historique:
pubmed: 31 8 2020
medline: 5 10 2021
entrez: 1 9 2020
Statut: ppublish

Résumé

English cervical screening programme guidelines changed between 2009 and 2012. We explore the impact on the age and intervals at which women receive a cytology test. Eligible women were controls from a population-based case-control study in England. Tests taken between 1980 and 2017 were extracted from the call/recall database. Using the Kaplan-Meier estimator by birth cohort and age at (or time since) last test, we explore proportions tested since or prior to a given age, years since previous test, and interval following a negative test. Screening histories from 46,037 women were included. Proportion tested by age 26 has increased from 55% among birth cohorts 1978-1979 to 67% among those born 1990-1991, despite more recent cohorts only having received one invitation (instead of two) prior to age 26. The proportion of women tested at aged 28 with a test three years earlier increased by 20% (from 36% in 1997-2006 to 56% in 2012-2017) whereas the proportion tested at ages 23-27 without a prior test increased from 34% to 80%. The age at last test prior to exiting the programme has decreased: among those born 1928-1931 86% had a test aged 60-65, but only 71% of those born 1947-1951. Clear programme guidance alongside quality assurance has improved the cervical screening programme by standardising the age and intervals at which women are screened.

Sections du résumé

BACKGROUND
English cervical screening programme guidelines changed between 2009 and 2012. We explore the impact on the age and intervals at which women receive a cytology test.
METHODS
Eligible women were controls from a population-based case-control study in England. Tests taken between 1980 and 2017 were extracted from the call/recall database. Using the Kaplan-Meier estimator by birth cohort and age at (or time since) last test, we explore proportions tested since or prior to a given age, years since previous test, and interval following a negative test.
RESULTS
Screening histories from 46,037 women were included. Proportion tested by age 26 has increased from 55% among birth cohorts 1978-1979 to 67% among those born 1990-1991, despite more recent cohorts only having received one invitation (instead of two) prior to age 26. The proportion of women tested at aged 28 with a test three years earlier increased by 20% (from 36% in 1997-2006 to 56% in 2012-2017) whereas the proportion tested at ages 23-27 without a prior test increased from 34% to 80%. The age at last test prior to exiting the programme has decreased: among those born 1928-1931 86% had a test aged 60-65, but only 71% of those born 1947-1951.
CONCLUSION
Clear programme guidance alongside quality assurance has improved the cervical screening programme by standardising the age and intervals at which women are screened.

Identifiants

pubmed: 32862772
doi: 10.1177/0969141320953446
pmc: PMC8366121
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

325-332

Subventions

Organisme : Cancer Research UK
ID : C8162/A16892
Pays : United Kingdom

Références

Milbank Q. 2012 Mar;90(1):5-37
pubmed: 22428690
Eur J Cancer. 2009 Oct;45(15):2671-8
pubmed: 19695867
PLoS Med. 2014 Jan;11(1):e1001585
pubmed: 24453946
PLoS Med. 2017 Oct 24;14(10):e1002414
pubmed: 29065127
Br J Cancer. 2013 Jul 9;109(1):35-41
pubmed: 23820257
BMJ. 2019 Feb 6;364:l240
pubmed: 30728133
J Med Screen. 2012 Jun;19(2):89-93
pubmed: 22653575
Prev Med. 2018 Feb;107:21-28
pubmed: 29247658

Auteurs

Alejandra Castanon (A)

School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.

Shama Sheikh (S)

School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.

Philippa Pearmain (P)

Public Health England Screening, Screening Quality Assurance Service, Birmingham, UK.

Peter Sasieni (P)

School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH